Agilon Health, Inc. (AGL) Financial Ratios
7 years of historical data (2019–2025) · Healthcare · Medical - Care Facilities
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
14.87
↑+173% vs avg
5yr avg: 5.45
30Y Low1.7·High9.2
ROE
↓
-135.6%
↑-110% vs avg
5yr avg: -64.6%
30Y Low-136%·High-10%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
AGL Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Agilon Health, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.9B | $285M | $781M | $5.1B | $6.6B | $10.1B | — | — |
| Enterprise Value | $1.8B | $148M | $631M | $5.1B | $6.2B | $9.1B | — | — |
| P/E Ratio → | -4.64 | — | — | — | — | — | — | — |
| P/S Ratio | 0.32 | 0.05 | 0.13 | 1.19 | 2.76 | 6.62 | — | — |
| P/B Ratio | 14.87 | 2.25 | 1.66 | 7.76 | 6.33 | 9.22 | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
AGL EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.02 | 0.10 | 1.17 | 2.59 | 5.96 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
AGL Profitability
Margins and return-on-capital ratios measuring operating efficiency
Agilon Health, Inc. earns an operating margin of -7.1%. Operating margins have compressed from -5.4% to -7.1% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -135.6% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | -3.2% | -3.2% | 0.1% | 1.6% | 4.7% | 4.3% | 7.7% | 3.6% |
| Operating Margin | -7.1% | -7.1% | -4.8% | -5.4% | -4.4% | -24.5% | -4.7% | -13.4% |
| Net Profit Margin | -6.8% | -6.8% | -4.3% | -6.1% | -4.5% | -26.7% | -4.9% | -35.6% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -135.6% | -135.6% | -46.0% | -30.9% | -10.0% | -100.8% | — | — |
| ROA | -27.0% | -27.0% | -15.0% | -15.3% | -6.5% | -40.0% | -14.1% | -70.2% |
| ROIC | -203.2% | -203.2% | -47.6% | -28.4% | -21.8% | -289.6% | — | — |
| ROCE | -108.4% | -108.4% | -43.4% | -24.1% | -8.8% | -52.8% | -29.6% | -52.5% |
AGL Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $174M exceeds total debt of $37M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.29 | 0.29 | 0.09 | 0.08 | 0.05 | 0.05 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.08 | -0.32 | -0.09 | -0.40 | -0.91 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | -59.85 | -59.85 | -39.28 | -28.21 | -19.22 | -61.31 | -6.66 | -11.65 |
Net cash position: cash ($174M) exceeds total debt ($37M)
AGL Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.02x means Agilon Health, Inc. can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has declined from 1.51x to 1.02x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.02 | 1.02 | 1.27 | 1.51 | 2.71 | 3.83 | 1.10 | 1.23 |
| Quick Ratio | 1.02 | 1.02 | 1.27 | 1.51 | 2.71 | 3.83 | 1.10 | 1.23 |
| Cash Ratio | 0.26 | 0.26 | 0.35 | 0.51 | 1.64 | 2.96 | 0.40 | 0.62 |
| Asset Turnover | — | 4.67 | 3.50 | 2.48 | 1.41 | 0.96 | 2.73 | 1.97 |
| Inventory Turnover | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 41.45 | 61.25 | 79.70 | 75.25 | 70.39 | 43.31 | 42.85 |
AGL Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Agilon Health, Inc. returns 0.2% to shareholders annually primarily through share buybacks.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.2% | 1.1% | 0.0% | 3.9% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.2% | 1.1% | 0.0% | 3.9% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $17M | $16M | $16M | $16M | $15M | $15M | $15M |
Peer Comparison
Compare AGL with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 AGLYou | $2B | -4.6 | — | — | -3.2% | -7.1% | -135.6% | -203.2% | — |
 CNC | $30B | -4.5 | — | 7.0 | 12.2% | -3.9% | -28.7% | -21.6% | — |
 HUM | $43B | 36.7 | 22.9 | 115.5 | 14.5% | 1.1% | 7.0% | 4.1% | 5.7 |
 CVS | $125B | 70.7 | 14.0 | 16.1 | 13.8% | 2.6% | 2.3% | 5.0% | 6.2 |
 ELV | $84B | 15.5 | 11.2 | 26.6 | 25.6% | 4.1% | 13.3% | 9.1% | 3.4 |
 MOH | $10B | 21.9 | 10.1 | — | 9.0% | 1.7% | 11.0% | 17.4% | 4.0 |
 OSCR | $7B | -16.8 | — | 7.0 | 14.4% | -3.4% | -44.4% | — | — |
 CLOV | $3B | -29.4 | — | — | 18.5% | -4.4% | -26.3% | -34.0% | — |
 ALHC | $4B | -5908.1 | 93.4 | 39.5 | 12.4% | 0.4% | -0.5% | — | 7.5 |
 DOCS | $4B | 20.9 | 16.8 | — | 89.1% | 33.3% | 19.3% | 19.8% | 0.0 |
 UNH | $364B | 30.3 | 17.9 | 22.6 | 18.5% | 4.2% | 11.8% | 9.2% | 3.4 |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 7 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
AGL — Frequently Asked Questions
Quick answers to the most common questions about buying AGL stock.
What is Agilon Health, Inc.'s P/E ratio?
Agilon Health, Inc.'s current P/E ratio is -4.6x. This places it at the 50th percentile of its historical range.
What is Agilon Health, Inc.'s ROE?
Agilon Health, Inc.'s return on equity (ROE) is -135.6%. The historical average is -64.6%.
Is AGL stock overvalued?
Based on historical data, Agilon Health, Inc. is trading at a P/E of -4.6x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Agilon Health, Inc.'s profit margins?
Agilon Health, Inc. has -3.2% gross margin and -7.1% operating margin.